IL1B and Chagas disease: Thus, an increased level of IL1B expression has been observed in CCC patients, which has led to propose the different activation pathways of this cytokine as a therapeutic target to prevent the evolution of cardiomyopathy, fibrosis and inflammation in Chagas disease [62].